Genentech Inc., of South San Francisco, a unit of the Roche Group, said one of two Phase III studies testing monthly Lucentis (ranibizumab) in patients with diabetic macular edema met its primary endpoint. The study, designated RISE, showed that a significantly higher percentage of patients receiving Lucentis achieved an improvement in vision of at least 15 letters on the eye chart at 24 months compared to those in the placebo group. The study enrolled 377 patients.